Government Acknowledges Need for Stronger Regulation
The Centre acknowledged the need to strengthen the existing regulatory mechanism to prevent pharmaceutical companies from engaging in unethical marketing activities.
According to the government’s submission, detailed discussions had taken place to explore possible solutions. The proposed committee was to examine whether a statutory framework was necessary and, if so, recommend the appropriate legal provisions to ensure ethical practices across the pharmaceutical sector.
UCPMP 2024 to Remain Applicable
Pending the committee’s report and the government’s subsequent decision, the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, will continue to govern pharmaceutical marketing practices, as stated by the Centre before the Court.
The development could prove significant for pharmaceutical companies, marketing teams, medical representatives and healthcare professionals, as the proposed recommendations may influence the future regulatory framework for pharmaceutical promotion in India.
The committee’s recommendations and the government’s subsequent response will be important developments to watch in the ongoing effort to strengthen ethical standards in pharmaceutical marketing.
Source: Supreme Court proceedings and submissions made by the Central Government, as reported in the news report.
Disclaimer: This article is an editorial rewrite of the supplied news report. Readers should refer to the relevant court order and official government communications for authoritative details.
#PharmaNewsLive #PharmaNews #SupremeCourt #PharmaceuticalIndustry #UCPMP2024 #PharmaRegulations #EthicalMarketing #IndianPharma
